The 2024 Edition of this oversight provision distinguishes case-specific withholding from supplying information and justification to committee leadership. Its annual-report wording also carries a termination note referring to December 2021. Cross-referenced provisions and later changes have not been collated, so current application remains unverified. This is historical statutory context for programme-access claims, not evidence that a UAP programme existed or anyone obtained access.
■ Complete returned historical section; current application unreviewed
Garry Nolan, Congressionally Directed Medical Research Programs. cdmrp.health.mil.
The public Defense programme booklet identifies Nolan as the OCRP2011 Teal Innovator. His perspective reports ovarian-cancer cohort classification and describes hoped-for clinical benefits. This documents a public biomedical programme association; it establishes no classified UAP approach or access.
■ Selected Nolan perspective and programme context read
A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach